In addition to HLA, KIR3DL3 was more recently discovered as a novel interaction partner for HHLA2 (a immune checkpoint member of the B7 family), which has both immune inhibitory and activating abilities and is expressed in many human cancers (Wei et al., 2021). This evidence concerns the gene KIR3DL3 and cancer.